Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Insulinoma 4Hypoglycemia 4Congenital Hyperinsulinism 4Neuroendocrine Tumors 3Neuroblastoma 3Hyperinsulinism 3Pheochromocytoma 2Parkinson Disease 2Carcinoid Tumor 2Thyroid cancer, medullary 1Parathyroid Neoplasms 1Paraganglioma 1Multiple Endocrine Neoplasia 1Lewy Body Disease 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hypercalcemia 1Glucose Metabolism Disorders 1Endocrine System Diseases 1Brain Neoplasms 1Beckwith-Wiedemann Syndrome 1

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 13-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, medullary × fluorodopa F 18 × Endocrine × Clear all
NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡